Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Core Insights - Corvus Pharmaceuticals has published preclinical data on soquelitinib, an ITK inhibitor, indicating its potential to modulate tumor immunity, which is a novel approach in cancer immunotherapy [1][2][3] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a new immunotherapy strategy for various cancers and immune diseases [5] - The lead product candidate, soquelitinib, is an investigational oral small molecule drug that selectively inhibits ITK [6] Research Findings - The publication details soquelitinib's mechanism of action, which includes suppressing Th2 and Th17 cytokine production while sparing Th1 cytokines, enhancing the effector function of cytotoxic CD8 positive T cells, and increasing memory T cells with improved effector function [2][3] - The research was conducted in collaboration with several academic institutions, including the University of Michigan and Stanford University [3] Clinical Development - Corvus is currently enrolling patients in a Phase 3 clinical trial for relapsed peripheral T cell lymphoma (PTCL) and a Phase 1 clinical trial for moderate to severe atopic dermatitis [4][6] - Plans are in place to initiate a Phase 1 clinical trial of soquelitinib in patients with solid tumors [4]